°éËæÕï¶Ï£¨companion diagnostic£¬CDx£©ÊÇÒ»ÖÖÌåÍâÕï¶Ï¼¼Êõ£¬Äܹ»ÌṩÓйػ¼ÕßÕë¶ÔÌض¨ÖÎÁÆÒ©ÎïµÄÖÎÁÆ·´Ó¦µÄÐÅÏ¢£¬ÓÐÖúÓÚÈ·¶¨Äܹ»´ÓijһÖÎÁƲúÆ·ÖлñÒæµÄ»¼ÕßȺÌ壬´Ó¶ø¸ÄÉÆÖÎÁÆÔ¤ºó²¢½µµÍ±£½¡¿ªÖ§¡£´ËÍ⣬°éËæÕï¶Ï»¹ÓÐÖúÓÚÈ·¶¨×îÓпÉÄÜÕë¶ÔÖÎÁÆÒ©Îï²úÉúÏìÓ¦µÄ»¼ÕßȺÌå¡£
ΪÁ˽âÄÄЩ²¡ÈË¿ÉÒÔÊÜÒæÓÚ°ÐÏòÒ©ÎïÖÎÁÆ£¬»òÕßÄÄЩ²¡È˲»ÄܽÓÊÜ°ÐÏòÒ©ÎïÖÎÁÆ£¬FDA£¨ÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö£©ÓëÒ©ÎïºÍÉ豸ÖÆÔìÉ̽«¡°¿ª·¢Ä³Ð©²âÊÔ¡±£¬²¢³Æ֮Ϊ¡°°éËæÕï¶Ï¡±¡£
°éËæÕï¶ÏÊг¡¿Éϸ·ÖΪÖ×Áöѧ¡¢ÐÄѪ¹Ü¼²²¡¡¢ÖÐÊàÉñ¾ÏµÍ³¡¢Ñ×Ö¢¼°²¡¶¾Ñ§¡£ÆäÖУ¬Ö×ÁöѧÊÇ°éËæÕï¶ÏÊг¡´´ÊÕ×î¸ßµÄ¼²²¡ÁìÓò£¬Ä¿Ç°ÒÑ¿ª·¢Á˶àÖÖ°éËæÕï¶ÏÊÔ¼ÁºÐÓÃÓÚ¸÷Àà°©Ö¢ÉúÎï±êÖ¾ÎïµÄ¼ì²â£¬¸Ãϸ·ÖÊг¡µÄÖ÷ÒªÇý¶¯Á¦ÊÇ°ÐÏòÐÔÒ©ÎïÑз¢µÄÔö³¤£¬ÐèÒªÏàÓ¦µÄ°éËæÕï¶ÏÊÔ¼ÁºÐµÄ¿ª·¢¡£
ͼ1 CDxÓëÒ©ÎïÑз¢
Ä¿Ç°£¬FDAÒѾͨ¹ýÉÏÊÐÊýÊ®ÖÖ°éËæÕï¶ÏÊÔ¼ÁºÐ¼°ÏàÓ¦É豸£¬ÆäÖУ¬14¸öÕï¶ÏÓÃ;µÄÍõ¥¿¹Ïà¹Ø²úÆ·Òѱ»Åú×¼£¬Éæ¼°·ÇСϸ°û·Î°©¡¢ÈéÏÙ°©µÈ²»Í¬Ö×ÁöÀàÐ͵İéËæÕï¶Ï¡£
ͼ2 ²¿·ÖFDAͨ¹ýCDxÃûµ¥
HER-2ʵ¼ÊÉÏÊÇÒ»ÖÖÔ°©»ùÒòµÄÃû³Æ£¬È«³Æ½Ð×öÈËÀà±íƤÉú³¤Òò×ÓÊÜÌå2£¬ÊÇÒ»ÖÖ¿çĤÊÜÌåÑùµÄµ°°×£¬¾ßÓÐÀÒ°±ËἤøµÄ»îÐÔ£¬ÔÚÁÙ´²Öмì²âHER-2»ùÒòµÄ±í´ïÖ÷ÒªÊDzÉÓÃÃâÒß×黯ºÍÓ«¹âÔλÔÓ½»µÄ·½·¨£¬¶øHER-2µÄÀ©Ôö»òÕß²»±í´ï£¬³£³£ÊÇ·¢ÉúÔÚÈéÏÙ°©£¬ÉÙÊý¿ÉÒÔ·¢ÉúÔÚθ°©µÄ²¡ÈË¡£
PATHWAY anti HER-2/neu (4B5)Íõ¥¿Ë¡³õ¼¶¿¹ÌåÊÇÓÉÂÞÊÏÑз¢µÄÒ»ÖÖÍõ¥¿Ë¡¿¹Ì壬¹©ÊµÑéÊÒʹÓá£ÔÚBenchMark ULTRAÒÇÆ÷ÉÏʹÓÃultraViewͨÓÃDAB¼ì²âÊÔ¼ÁºÐ£¬Í¨¹ýÃâÒß×éÖ¯»¯Ñ§£¨IHC£©¶Ô¸£¶ûÂíÁ̶ֹ¨¡¢Ê¯À¯°üÂñµÄÕý³£ºÍÖ×ÁöÐÔÈéÏÙ×éÖ¯ÇÐƬ½øÐа붨Á¿¼ì²â¡£
PATHWAY anti HER-2/neu(4B5)ÊÊÓÃÓÚʶ±ð·ûºÏºÕÈüÍ¡?£¨IHC 3+»òIHC 2+/ISHÀ©Ôö£©¡¢KADCYLA?£¨IHC 3+»òIHC 2+/ISHÀ©Ôö£©»òENHERTU?£¨IHC 1+»òIHC 2+/ISH·ÇÀ©Ôö£©ÖÎÁƵÄÈéÏÙ°©»¼Õß¡£ÓëÆäËûÊг¡ÉϵÄHER2¿Ë¡Ïà±È£¬ÂÞÊÏHER2(4B5)¿Ë¡±íÏÖ³ö×îÎȶ¨µÄÐÔÄܺÍ׿ԽµÄÖÊÁ¿¡£
ͼ3 PATHWAY anti HER-2/neu(4B5)ÓëÆäËû¿Ë¡¶Ô±È
³ÌÐòÐÔËÀÍöÅäÌå1£¨PD-L1£©ÊÇÒ»ÖÖ¿çĤµ°°×£¬Í¨¹ýÓëËüµÄÁ½¸öÒÖÖÆÐÔÊÜÌ塪¡ª³ÌÐòÐÔËÀÍöÊÜÌå-1£¨PD-1£©ºÍB7.1¡ª¡ª½áºÏ¶øϵ÷ÃâÒß·´Ó¦¡£PD-1ÊÇTϸ°û¼¤»îºóÔÚTϸ°ûÉϱí´ïµÄÒ»ÖÖÒÖÖÆÐÔÊÜÌ壬ÔÚÂýÐԴ̼¤×´Ì¬Ï£¬ÈçÂýÐÔ¸ÐȾ»ò°©Ö¢£¬PD-1µÄ½áºÏ»áÒÖÖÆTϸ°ûµÄÔöÖ³¡¢Ï¸°ûÒò×ӵIJúÉúºÍϸ°ûÈܽâ»îÐÔ£¬µ¼ÖÂTϸ°û¹¦ÄÜʧ»î»òË¥½ß¡£ÖжÏPD-L1/PD-1ͨ·ÊÇÒ»ÖÖÓÐЧµÄ²ßÂÔ£¬¿ÉÒÔÖØÕñ±»Ö×Áö΢»·¾³ÖÐPD-L1±í´ïÒÖÖƵÄÖ×ÁöÌØÒìÐÔTϸ°ûÃâÒß¡£
ͼ4 PD-L1ÃâÒß¼ì²éµã
VENTANA PD-L1 (SP142)ÊÔ¼ÁÊÇÂÞÊϵÄÒ»ÖÖ¶¨ÐÔµÄÃâÒß×黯¼ì²âÊÔ¼Á£¬Ê¹ÓÃÍõ¥¿Ë¡¿¹PD-L1¿Ë¡SP142£¬ÓÃÓÚÆÀ¹ÀÏÂÁи£¶ûÂíÁ̶ֹ¨¡¢Ê¯À¯°üÂñ£¨FFPE£©×éÖ¯ÖеÄPD-L1µ°°×£¬ÔÚBenchMark ULTRAÒÇÆ÷ÉÏÓÃOptiView DAB IHC¼ì²âÌ×¼þºÍOptiViewÀ©ÔöÌ×¼þ½øÐÐȾɫ¡£
ͼ5 VENTANA PD-L1(SP142)ÊÔ¼ÁµÄ¸¨ÖúÕï¶ÏÊÊÓ¦Ö¢
¸ù¾ÝÖÎÁÆÉ趨£¬ÔÚ·ÇСϸ°û·Î°©£¨NSCLC£©»¼ÕßÖУ¬Í¨¹ýVENTANA PD-L1£¨SP142£©¼ì²â·¨È·¶¨µÄPD-L1±í´ïÁ¿TC¡Ý50%»òIC¡Ý10%¿ÉÄÜÓëTECENTRIQ£¨atezolizumab£©µÄ×ÜÉú´æÂÊÌá¸ßÓйء£
VENTANA PD-L1 (SP263)ͬÑùÊÇÓÃÓÚʶ±ð·ûºÏTECENTRIQ (atezolizumab)ÖÎÁƵÄÔçÆÚNSCLC»¼ÕßµÄÍõ¥¿Ë¡³õ¼¶¿¹Ìå¡£ËüÊÇÓÃÓÚ¼ì²âʵÑéÊҵĸ£¶ûÂíÁ̶ֹ¨¡¢Ê¯À¯°üÂñ×éÖ¯ÖеÄPD-L1µ°°×£¬¿É×÷ΪÆÀ¹ÀÈËÀà×éÖ¯ÖÐPD-L1±í´ïµÄ¸¨Öú¹¤¾ß¡£
ͼ6 ÂÞÊÏÆäËû°éËæÕï¶Ï
Ïà¶ÔIVDÁìÓòÆäËûÕï¶Ï·½Ê½£¬°éËæÕï¶ÏÄ¿Ç°ÈÔ´¦ÓÚÊг¡·¢Õ¹³õÆڽ׶Σ¬Í¨¹ýFDAÈÏÖ¤µÄÊÐÊÛ²úÆ·Ò²Ïà¶Ô½ÏÉÙ¡£Íõ¥¿¹ÓÉÓÚÆä±¾ÉíÁéÃô¶È¸ß£¬Ê¶±ð±íλ¸ü¾«Ï¸µÈÓÅÊÆ£¬¸üÊʺÏ×÷Ϊ°éËæÕï¶Ï¿¹Ìå½øÐÐIHC¼ì²âʹÓ㬰ïÖú»¼Õ߸üºÃµÃ½øÐÐÖÎÁÆ£¬²¢½µµÍÖÎÁƳɱ¾£¬ÒѳÉΪ¸÷´óÕï¶ÏÆóÒµµÄÑо¿·½ÏòÖ®Ò»¡£
²Î¿¼ÎÄÏ×
[1]Blank, C and Mackensen, A, Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother, 2007. 56(5): p. 739-745.
[2]Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111-122.
[3]Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365-1369.
[4]Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
[5]Mayr D, et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest? (Dako) for manual testing and Her2/neuTest 4B5 (VENTANA) for VENTANA BenchMark automatic staining system with correlation to results of BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Archiv. 2009; 454(3):241¨C248.
Br¨¹gmann A, Lelkaitis G, Nielsen S, et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol. 2011;19(3):203-211.
ËÕ¹«Íø°²±¸
ËÕICP±¸ºÅ-1
|